The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly (NYSE: LLY), for the treatment of moderately to severely active Crohn's disease in adults.
Omvoh, which is seen as a potential growth driver by Lilly, is now approved in the USA for two types of inflammatory bowel disease (IBD), following its October 2023 authorization as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults.
The authorization builds up the competitive position of Omvoh in the increasingly competitive inflammatory bowel disease (IBD) market, where it competes with other interleukin (IL)-23 inhibitors, including AbbVie's (NYSE: ABBV) Skyrizi (risankizumab), Johnson & Johnson's (NYSE: JNJ) Stelara (ustekinumab) and Tremfya (guselkumab), as well as Sun Pharma's Ilumya (tildrakizumab). GlobalData has forecast that sales of Omvoh will reach $1.2 billion around the end of the decade
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze